Coronavirus variant JN.1: All you need to know

The JN.1 coronavirus variant has alarmed both health professionals and the general public. This sub-variant was discovered in Luxembourg and is a descendent of the Pirola variety (BA.2.86), which is a descendant of the Omicron sub-variant.

A subvariant of Omicron, is believed to be the COVID JN.1 variant. This case was initially identified in the United States in September of this year. On December 15, Reuters reported the discovery of seven cases of this specific subvariant in China. The CDC noted in a recent update, "Even though BA.2.86 and JN.1 sound very different because of the way variants are named, there is only a single change between JN.1 and BA.2.86 in the spike protein."

Following the identification of the JN.1 variety in India, the Central government issued a warning to states on Monday, encouraging them to "remain vigilant." On December 8, 2023, the first case of JN.1 was discovered in a positive RT-PCR sample in Karakulam, Thiruvananthapuram, Kerala. The bulk of instances have been documented in Kerala, Karnataka, Tamil Nadu, and Odisha.

What is Covid virus JN.1?

JN.1 is a new variant of the Omicron subvariant BA.2.86, distinguished by an extra mutation in the spike protein. This variation has the ability to spread quickly and elude immunity, emphasising the importance of ongoing surveillance and prudence in India.

How dangerous is the JN.1 variant

Chief Dr. NK Arora of the Indian SARS-COV-2 Genomics Consortium (INSACOG), a network of laboratories that monitors genomic variants of the COVID-19 virus, reassured, "There is no need for panic regarding the JN.1 subvariant. Although the number of samples is limited, they are being collected from all states. INSACOG is diligently overseeing the situation, conducting a thorough analysis of the epidemiology and clinical behavior of the virus."

JN.1 symptoms

JN.1 symptoms are comparable to previous strains of the virus, including fever, runny nose, sore throat, headache, and moderate gastrointestinal symptoms such as abdominal pain and diarrhoea.

According to reports, this newer variety may be more prone to gastrointestinal issues, though further research is needed to back up these claims.

As per the CDC, the variety and intensity of symptoms an individual undergoes typically rely more on the individual's underlying health and immunity than on the specific variant causing the infection. Some medical professionals have observed that upper respiratory symptoms tend to manifest in a sequence, beginning with a sore throat and progressing to congestion and cough.

Precautions JN.1

The reassuring news is that the same preventive measures that have proven effective against previous variants remain applicable for JN.1:

• Get vaccinated and boosted: Vaccination remains the most effective means to safeguard yourself from severe Covid-19 illness, hospitalization, and death.
• Wear a mask in crowded settings: Utilizing a well-fitting mask, particularly in crowded indoor spaces or while using public transportation, can significantly reduce the risk of transmission.
• Maintain social distancing: Keeping a safe distance from others, especially those who are unwell, can contribute to preventing the spread of the virus.
• Practice good hand hygiene: Regular handwashing with soap and water or using an alcohol-based hand sanitizer is essential for averting the spread of germs.

Are vaccines, tests, and treatments effective against JN.1?

Currently, the indications are optimistic. According to the CDC, COVID-19 tests and treatments are anticipated to be efficacious against JN.1. Although the most recent COVID-19 booster shot was specifically formulated to target the XBB.1.5 variant, initial research suggests that it also stimulates the production of antibodies that function against JN.1, albeit in lower quantities. (As always, vaccines may not completely prevent JN.1 infections but are expected to decrease the likelihood of death and severe illness.) In a statement issued on December 13, the WHO's expert COVID-19 vaccine advisory group recommended adhering to the existing XBB.1.5 vaccines, as they appear to offer at least some cross-protection.